Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

What Has Investors Spooked About These 4 Stocks Today?

Page 1 of 2

Halloween is approaching, where kids young and old roam the streets as ghosts, zombies, and other creatures of the night. Yet it’s not the looming threat of cities being overrun by little monsters that has investors frightened this morning, but the horror stories being woven by a handful of companies, whose stocks are under heavy selling pressure as a result. Let’s unmask the news haunting investors and see how long the trembling is likely to persist.

stocks, analysis, market, numbers, business, ticker, trade, money, price, investment, index, chart


We’ll start with Rovi Corporation (NASDAQ:ROVI), which has tumbled by just over 20% after its third quarter earnings missed the mark after its deal with an unnamed major consumer electronics manufacturer expired. Rovi Corporation (NASDAQ:ROVI) further warned that the low-end of its full-year guidance would be missed if a deal with that manufacturer was not renewed, negotiations towards which are currently being held. For its third quarter, profit slid to $0.29 per share, down from $0.42 EPS a year ago, and short of the $0.36 consensus estimate. Revenue also slid by more than 10% year-over-year to $114.88 million. Rovi Corporation (NASDAQ:ROVI) shares have now crumbled by more than 60% this year. The elite investors that we track were wisely vacating the stock in the second quarter, as ownership fell to 20 from 32.

Follow Rovi Corp (NASDAQ:ROVI)
Trade (NASDAQ:ROVI) Now!

Whether elite hedge funds collectively like a stock or not is an important metric to consider, as these large investors show a great level of skill and expertise when it comes to picking stocks. Over the last few years equity hedge funds have trailed the market by a large margin, but that’s mostly due to their hedging and short positions, which perform poorly in a bull market. Their long positions performed far better, especially their small-cap picks, which have the potential to beat the market by 95 basis points per month on average, as our backtests showed. Our small-cap strategy involves imitating a portfolio of the 15 most popular small-cap picks among hedge funds and it has returned 102% since August 2012, beating the S&P 500 ETF (SPY) by over 53 percentage points (read more details here).

A popular food stock among elite investors, GNC Holdings Inc. (NYSE:GNC) has disappointed today, falling by 25% after earnings and revenue both fell from a year ago, while analysts had been expecting an improvement. Earnings came in at $0.54 per share, widely missing estimates of $0.83, while revenue of $672.2 million missed by over $11 million. EPS and revenue were down by 24% and 2.7% respectively, year-over-year. It’s the second big blow in the past week for GNC Holdings Inc. (NYSE:GNC), which fell by 15% on October 22 after Oregon’s Attorney General filed a lawsuit against it alleging the use of the illegal ingredients BMPEA and picamilon in its supplements. GNC Holdings Inc. (NYSE:GNC) refuted the allegations, claiming they are “without merit”. Shares have now declined by over 38% year-to-date, a big blow to the bullish investors in our database, which held 27.00% of those shares on June 30, led by Ricky Sandler‘s Eminence Capital.

Follow Gnc Holdings Inc. (NYSE:GNC)
Trade (NYSE:GNC) Now!

On the next page we have the details on two more stocks, NXP Semiconductors and ABIOMED, that have given investors a good scare this morning.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!